- Home
- LTH vs INM Comparison
LTH vs INM Comparison
Compare LTH & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTH | INM |
|---|---|---|
| Founded | 1992 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 7.1M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LTH | INM |
|---|---|---|
| Price | $40.87 | $1.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $40.57 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 58.8K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.32 | 62.68 |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $2,995,255,000.00 | $4,942,633.00 |
| Revenue This Year | $11.98 | N/A |
| Revenue Next Year | $11.45 | N/A |
| P/E Ratio | $50.29 | ★ N/A |
| Revenue Growth | ★ 14.28 | 7.50 |
| 52 Week Low | $24.14 | $0.58 |
| 52 Week High | $47.24 | $2.50 |
Technical Indicators
Market Signals| Indicator | LTH | INM |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 35.71 |
| Support Level | $41.74 | $1.03 |
| Resistance Level | $43.96 | $1.40 |
| Average True Range (ATR) | 1.18 | 0.06 |
| MACD | -0.24 | -0.01 |
| Stochastic Oscillator | 34.09 | 13.04 |
Price Performance
Historical ComparisonAbout LTH Life Time Group Holdings Inc.
Life Time Group Holdings Inc is a lifestyle and leisure brand offering health, fitness, and wellness experiences to a community. It is engaged in designing, building, and operating distinctive and large, multi-use sports and athletic, professional fitness, family recreation, and spa centers in a resort-like environment, principally in residential locations of metropolitan areas in the United States and Canada.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.